89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event of pegozafermin’s opportunity in advanced metabolic dysfunction-associated ste...
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data highlighting the potential of the Company’s HSV-1 based vector platform for back of the eye gene delivery at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held from May 5-9, 2024 in Seattle, Washington. Poster presentation details are as follows: Ti...
Adeia Enters into Long-Term IP License Agreement with Astound Broadband SAN JOSE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), the company whose patented innovations shape the way the world explores and experiences entertainment, has entered into an agreement with Astound Broadband, a leading provider of digital TV, high-speed internet and phone services for residential and business customers across the United States, to license Adeia’s media intellectual property (IP) portfolio. National demand for pay-TV and high-speed internet services has undergone notable ch...
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 6, 2024, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For those unable ...
Ethan Allen Reports Fiscal 2024 Third Quarter Results Highlighted by Robust Balance Sheet, Strong Cash Dividends and Double-Digit Operating Margin; Lower Demand Reflects Post Pandemic Period DANBURY, CT, April 24, 2024 (GLOBE NEWSWIRE) -- Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD), a leading interior design destination, today reported its financial and operating results for the fiscal 2024 third quarter ended March 31, 2024. Farooq Kathwari, Ethan Allen’s Chairman, President and CEO commented, “We are pleased with our financial performance and the continu...
NEW YORK--(BUSINESS WIRE)-- Inter Parfums, Inc. (NASDAQ GS: IPAR) (“Inter Parfums” or the “Company”) today announced that for the three months ended March 31, 2024, net sales rose to $324 million, up 4% from $312 million, in the first quarter of 2023. Net Sales: ($ in millions; data may not foot due to rounding) Three Months Ended March 31, 2024 2023 % Change Total Inter Parfums, Inc. $324 $312 4% European based product sales $231 $230 flat United States based product sales $96 ...
NEW YORK--(BUSINESS WIRE)-- Inter Parfums, Inc. (NASDAQ GS: IPAR) today announced that it will issue financial results for the three months ended March 31, 2024, on Tuesday, May 7, 2024, after the close of the stock market. Management will host a conference call to discuss financial results and business operations beginning at 11:00 am ET on Wednesday, May 8, 2024. Interested parties may participate in the live call by dialing: U.S. / Toll-free: (877) 423-9820 International: (201) 493-6749 Participants are asked to dial-in approximately 10 minutes before th...
Adeia Enters into Multi-year IP License Renewal with Altimedia SAN JOSE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), a company known for its groundbreaking innovations in entertainment experiences, has announced today that Altimedia, a provider of solutions for managing advanced media services, has signed a multi-year license renewal for access to Adeia’s media intellectual property (IP) portfolio. Altimedia offers a user experience (UX) platform to pay-TV and digital media service providers in the Korean market. Their platform empowers these providers with cutt...
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, MD, May 7 – 11, 2024. The poster will feature new preclinical data that dem...
Ethan Allen Increases Regular Quarterly Cash Dividend by 8.3% DANBURY, CT, April 22, 2024 (GLOBE NEWSWIRE) -- Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD) announced today that its Board of Directors declared and increased the regular quarterly cash dividend to $0.39 per share, payable on May 23, 2024, to shareholders of record at the close of business on May 7, 2024. Farooq Kathwari, Ethan Allen’s Chairman, President and CEO commented, “We are pleased to increase our regular quarterly cash dividend by 8.3% to $0.39 per share. The Board’s decision today highl...
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung • Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the first patient was dosed in its Phase 1 clinical trial (KYANITE-1) evaluating inhaled KB707, a modified HSV-1 vector designed to deliver genes encoding both human interleukin-12 (IL-12) and interleukin-2 (IL...
PLUMAS BANCORP DECLARES QUARTERLY CASH DIVIDEND RENO, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- Plumas Bancorp (Nasdaq:PLBC), the parent company of Plumas Bank (the “Bank”), today announced that the Board of Directors declared a regular quarterly cash dividend on Plumas Bancorp common stock of $0.27 per share, payable May 15, 2024, to stockholders of record as of May 1, 2024. About Plumas Bancorp Plumas Bank is a subsidiary of Plumas Bancorp (NASDAQ: PLBC), a bank holding company headquartered in Reno, Nevada. Plumas Bank is a locally managed, award-winning community bank founded in 1980...
Adeia Enters into IP License Agreement with Magenta Telekom SAN JOSE, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA) ("Adeia" or the "Company"), the company whose patented innovations shape the way the world explores and experiences entertainment, today announced Magenta Telekom, a leading provider of Internet, mobile communications, entertainment and business solutions, has entered into an agreement to license Adeia’s media intellectual property (IP) portfolio. According to analysts at Statista1, the vast majority of Austrian consumers (86%) report accessing digi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.